endostar/PD-1 inhibitor

PreclinicalSmall molecule

DDong Wang

endostar/PD-1 inhibitor is one of 3 small molecule programs targeting PD-1 Inhibitors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PD-1 InhibitorsUnknown status

PD-1 InhibitorsPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in PD-1 Inhibitors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

1 2

ASKB589

AAskGene Pharma, Inc.

Phase 2

1 3

endostar/PD-1 inhibitor

DDong Wang

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PD-1 Inhibitors1 trial

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Unknown status·DDong Wang·N/A·NCT04063449·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for endostar/PD-1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — endostar/PD-1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for endostar/PD-1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dong Wang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDong Wang

endostar/PD-1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PD-1 Inhibitors1 trial

References

Drug Info

Quick Facts

Related News